

**UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF TEXAS
SHERMAN DIVISION**

TIM DOYLE, Individually and on Behalf of All
Others Similarly Situated, *et al.*,

Plaintiffs,

v.

REATA PHARMACEUTICALS, INC., *et al.*

Defendants.

Case No. 4:21-cv-00987-ALM
LEAD

CLASS ACTION

**LEAD PLAINTIFF'S REPLY IN SUPPORT OF MOTION FOR AUTHORIZATION
TO DISTRIBUTE NET SETTLEMENT FUND TO AUTHORIZED CLAIMANTS**

Pursuant to Federal Rule of Civil Procedure 23(e), Lead Plaintiff UMC Benefit Board, Inc., US Equity Fund-P Series, a series of the Wespath Funds Trust, US Equity Index Fund-P Series, a series of the Wespath Funds Trust, Wespath Institutional Investments LLC, US Equity Fund-I Series, a series of the Wespath Funds Trust, and US Equity Index Fund-I Series, a series of the Wespath Funds Trust (“Lead Plaintiff”), on behalf of itself and the Settlement Class, respectfully submit this reply brief in support of the motion for authorization to distribute net settlement fund to authorized claimants (ECF No. 86) (the “Motion”).

The claims administrator posted the Motion on the Settlement Website.¹ The claims administrator also emailed the six (6) claimants requesting Court review of their claims to advise them of the deadline to respond to the Motion. A copy of the redacted email sent by the claims administrator to the claimants requesting Court review of their claims is attached as Exhibit A. The deadline for responses to the Motion was December 4, 2024. No responses have been received to date.

Because there is no opposition to the Motion and for the reasons articulated in the Motion, Lead Plaintiff respectfully requests that the Court enter an order authorizing the distribution of the net settlement fund to authorized claimants.

Dated: December 11, 2024

Respectfully Submitted,

STECKLER WAYNE & LOVE PLLC

/s/ Bruce W. Steckler

Bruce W. Steckler

State Bar No. 00785039

Austin P. Smith

State Bar No. 24102506

12720 Hillcrest Road, Suite 1045

¹ See <https://www.reatasecuritieslitigation.com/Home/Documents>.

Dallas, TX 75230
Telephone: 972-387-4040
Facsimile: 972-387-4041
Email: bruce@swclaw.com
austin@swclaw.com

*Local Counsel for Lead Plaintiff and the
Proposed Settlement Class*

KIRBY McINERNEY LLP
Daniel Hume (admitted *pro hac vice*)
Meghan J. Summers (admitted *pro hac vice*)
Ira M. Press (admitted *pro hac vice*)
250 Park Avenue, Suite 820
New York, NY 10177
Telephone: 212-371-6600
Facsimile: 212-751-2540
Email: dhume@kmlp.com
msummers@kmlp.com
ipress@kmlp.com

*Lead Counsel for Lead Plaintiff and the
Proposed Settlement Class*

GLANCY PRONGAY & MURRAY LLP
Charles H. Linehan
Pavithra Rajesh
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Telephone: (310) 201-9150
Facsimile: (310) 201-9160

*Additional Counsel for the Proposed
Settlement Class*

CERTIFICATE OF SERVICE

I hereby certify that on December 11, 2024, all counsel of record who are deemed to have consented to electronic service are being served with a copy of this document via the Court's CM/ECF Filing System.

/s/ Bruce Steckler

Bruce Steckler

[REDACTED]

From: Info_ReataSecuritiesLitigation
Sent: Friday, November 22, 2024 2:13 PM
To: [REDACTED]
Subject: Doyle v. Reata Pharmaceuticals Inc. - Claim Number 800000158

RE: [REDACTED]

Dear [REDACTED]

Pursuant to your request for court review of your claim, please note that your claim was filed with the court on November 20, 2024. You may review the distribution motion and the accompanying documents, including your disputed claim, on the settlement website at: [Reata Securities Litigation - Documents](#)

If you have any response or additional information you would like the court to consider, please note that your response is due by Wednesday, December 4, 2024.

Sincerely,

[REDACTED]
Claims Administrator
Doyle v. Reata Pharmaceuticals, Inc.
Email: info@ReataSecuritiesLitigation.com